Loading...
XHKG
1498
Market cap23mUSD
Jun 16, Last price  
0.47HKD
1D
-2.08%
1Q
-16.07%
Jan 2017
-87.43%
IPO
-90.05%
Name

PuraPharm Corp Ltd

Chart & Performance

D1W1MN
P/E
—
P/S
0.49
EPS
—
Div Yield, %
—
Shrs. gr., 5y
7.43%
Rev. gr., 5y
-11.30%
Revenues
382m
-6.09%
342,303,000366,352,000473,900,000535,986,000591,566,000745,503,000695,879,000601,815,000659,592,000448,069,000406,859,000382,090,000
Net income
-35m
L-66.59%
26,264,00034,463,00028,458,00032,162,0001,889,00020,806,000-227,258,00031,710,000-121,877,000-120,214,000-106,081,000-35,439,000
CFO
104m
+30.62%
11,034,00031,091,000-12,570,000-55,828,000-42,752,00072,461,000101,935,00086,682,000-39,327,00065,848,00079,608,000103,985,000
Dividend
May 31, 20170.0202 HKD/sh

Profile

PuraPharm Corporation Limited, an investment holding company, researches, develops, produces, and sells concentrated Chinese medicine granule (CCMG) and Chinese healthcare products in Hong Kong, Mainland China, and internationally. It operates through five segments: China CCMG, Hong Kong CCMG, Chinese Healthcare Products, Clinics, and Plantation. The company offers over the counter health products under the PuraGold, Haveron, Oncozac, and Immuzac names. It also provides Chinese medicine clinic management system for general clinic management; and operates Chinese medicine clinics under the Nong's name that provide Chinese medicine services and concentrated Chinese medicine granules products. In addition, the company engages in the plantation and trading of raw Chinese herbs; and manufacture and sale of traditional Chinese medicine decoction pieces. Further, it provides modernized Chinese medicine services; and Chinese medical diagnostic services. The company sells its products to hospitals, healthcare institutions, and medicine practitioners, as well as operates an online store. It operates 43 Nong's clinics in Hong Kong and 1 Nong's clinic in Guangxi, China. The company was founded in 1998 and is headquartered in Tai Po, Hong Kong.
URL
https://www.purapharm.com/
IPO date
Jul 08, 2015
Employees
650
Domiciled in
HK
Incorporated in
KY

Valuation

Title
HKD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
382,090
-6.09%
406,859
-9.20%
448,069
-32.07%
Cost of revenue
412,502
453,408
522,787
Unusual Expense (Income)
NOPBT
(30,412)
(46,549)
(74,718)
NOPBT Margin
Operating Taxes
6,295
3,769
1,032
Tax Rate
NOPAT
(36,707)
(50,318)
(75,750)
Net income
(35,439)
-66.59%
(106,081)
-11.76%
(120,214)
-1.36%
Dividends
Dividend yield
Proceeds from repurchase of equity
803
BB yield
-0.16%
Debt
Debt current
264,181
321,995
428,645
Long-term debt
123,627
142,429
74,512
Deferred revenue
1,076
1,025
Other long-term liabilities
13,882
14,044
39,055
Net debt
371,314
418,299
371,769
Cash flow
Cash from operating activities
103,985
79,608
65,848
CAPEX
(14,808)
(19,183)
(23,558)
Cash from investing activities
(11,711)
(18,203)
(25,445)
Cash from financing activities
(86,429)
(122,390)
(12,937)
FCF
35,224
66,902
124,414
Balance
Cash
12,794
47,221
107,014
Long term investments
3,700
(1,096)
24,374
Excess cash
25,782
108,985
Stockholders' equity
111,198
(68,335)
39,577
Invested Capital
488,839
661,461
735,703
ROIC
ROCE
EV
Common stock shares outstanding
395,053
395,053
394,585
Price
0.55
-38.89%
0.90
-29.69%
1.28
58.02%
Market cap
217,279
-38.89%
355,548
-29.60%
505,069
58.37%
EV
588,593
773,847
876,838
EBITDA
24,174
2,042
(26,057)
EV/EBITDA
24.35
378.97
Interest
27,407
24,183
Interest/NOPBT